Dopamine receptors in the basal ganglia: Relevance to parkinson's disease

Movement Disorders

Volumn 8, Issue 3, 1993, Pages 263-270

  Strange, Philip G ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Dopamine receptors; Drug treatment; Motor control; Neostriatum; Parkinson's disease

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT;

BASAL GANGLION; BRAIN TISSUE; CAUDATE NUCLEUS; DRUG MECHANISM; HUMAN; HUMAN TISSUE; PARKINSON DISEASE; PHARMACOLOGY; PUTAMEN; REVIEW; TISSUE DISTRIBUTION;

BASAL GANGLIA; BASAL GANGLIA DISEASES; BRAIN; CLOZAPINE; DOPAMINE AGENTS; FEMALE; HALOPERIDOL; HUMAN; LEVODOPA; MALE; NEOSTRIATUM; NEURAL PATHWAYS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SULPIRIDE;

EID: 0027291214     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.870080303     Document Type: Review

References (55)

1. 2 dopamine receptors
2. Molecular biology of dopamine receptors
3. 2 dopamine receptor
4. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones
5. 2 dopamine receptor regulated gene expression of striatonigral and striatopallidal neurones
6. 2 dopamine receptors differentially regulate c‐fos expression in striatonigral and striatopallidal neurones
7. 2 dopamine receptor mRNAs in rat brain
8. 2 dopamine receptor mRNA
9. Parallel organisation of functionally segregated circuits linking basal ganglia and cortex
10. Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, prefrontal, and limbic functions
11. Disinhibition as a basic process in the expression of striatal functions
12. Tyrosine hydroxylase immunoreactive boutons in synaptic contact with identified striatonigral neurones with particular reference to dendritic spines
13. The functional anatomy of basal ganglia disorders
14. Role of the mesostriatal dopamine pathway
15. The activity of pars compacta neurones of the monkey substantia nigra in relation to motor activations
16. The structure and mechanism of neurotransmitter receptors. Implications for the structure and function of the central nervous system
17. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease
18. Primate models of movement disorders of basal ganglia origin
19. Subcutaneous apomorphine in the treatment of Parkinson's disease
20. Manipulating the dopaminergic system in Parkinson's disease
21. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease
22. The motor effects of bromocriptine‐a review
23. 1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum
24. 2 agonists in MPTP‐treated primates. Functional implications for Parkinson's disease
25. Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393
26. 1 dopamine receptor partial agonist CY 208–243 exhibits antiparkinsonian activity in the MPTP treated marmoset
27. Selective D‐1 dopamine receptor agonist treatment of Parkinson's disease
28. 1 agonist, reduces MPTP induced parkinsonism in monkeys
29. 2 agonist in primates
30. Antiparkinsonian activity of CY 208–243 a partial D‐1 dopamine receptor agonist in MPTP treated marmosets and patients with Parkinson's disease
31. A double blind placebo‐controlled, dose ranging study to investigate the safety and efficacy of CY208–243 in patients with Parkinson's disease
32. 1 agonist, CY 208‐243, in de novo patients with Parkinson's disease
33. The effect of LY 171555 and CY 208‐243 on tremor suppression in the MPTP monkey model of parkinsonism
34. 3) as a target for neuroleptics
35. 2 receptor
36. Turing behaviour in animals
37. 1 receptor antagonist
38. A hypothesis on the pathophsiological mechanisms that underlie levodopa or dopamine agonist induced dyskinesia in Parkinson's disease: implications for future strategies in treatment
39. 2 agonists and antagonists on dyskinesias produced by l‐DOPA in 1‐methyl, 4‐phenyl, 1, 2, 3, 6 tetrahydropyridine treated monkeys
40. Continuous and intermittent levodopa differentially affect rotation induced by D‐1 or D‐2 dopamine agonists
41. 1 dopamine receptor
42. 1‐dopamine receptos linked to adenylyl cyclase activity in cultured NS20Y neuroblastoma cells
43. 2 dopamine receptors in human Y‐79 retinoblastoma cells
44. Dopamine receptors and transporters in Parkinson's disease and schizophrenia
45. A post‐mortem study on striatal dopamine receptors in Parkinson's disease
46. In vivo and in vitro studies of the dopaminergic system in movement disorders
47. The effect of chronic treatment of MPTP monkeys with dopamine D‐1 and/or D‐2 receptor agonists
48. PET demonstrates different behaviour of striatal dopamine D‐1 and D‐2 receptors in early Parkinson's disease
49. 3) as a novel target for antipsychotics
50. 1 dopamine receptor
51. 1
52. 3 receptor and chromosome identification
53. 4 receptor with high affinity for the antipsychotic clozapine
54. 4 receptor: sequence, gene structure and demonstration of expression in the cardiovascular system